3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
59
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Lung Neoplasms
25
Squamous Cell Carcinoma of Head and Neck
20
Melanoma
19
Neoplasm Metastasis
18
Neoplasms
16
Endometrial Neoplasms
14
Colorectal Neoplasms
14
Breast Neoplasms
14
Triple Negative Breast Neoplasms
12
Ovarian Neoplasms
11
Head and Neck Neoplasms
9
Carcinoma, Renal Cell
8
Pancreatic Neoplasms
7
Carcinoma, Transitional Cell
7
Urinary Bladder Neoplasms
6
Recurrence
5
Lymphoma
5
Hodgkin Disease
5
Esophageal Neoplasms
4
Carcinoma
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Prostatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Fallopian Tube Neoplasms
3
Interventions
pembrolizumab
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
avelumab
1
aldesleukin
1
Nivolumab
1
Cyclophosphamide
1
Axitinib
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
pembrolizumab
×
30 days
×
Clear all
NCT07302347
2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
20 enrolled